Clinical Trial Disclosure & Data Transparency Conference

Evolving Requirements and New Challenges

Back to Agenda

Session 2: UK Disclosure Requirements Updates'

Session Chair(s)

Scott Feiner

Senior Manager, Trial Disclosure

AbbVie, United States

In recent months, the United Kingdom’s disclosure requirements post-Brexit have come into greater focus.

This session provides updates from the HRA on their disclosure requirements, and a sponsor perspective on using the latest guidance documents to meet the clinical trial disclosure requirements of the UK.

Speaker(s)

Expanding Disclosure Requirements From the HRA

Naho Yamazaki, PhD

Health Research Authority, United Kingdom

Deputy Director, Policy and Partnerships

Example of Interventional, Non-Interventional and Device Trials A Sponsor Walkthrough of UK Clinical Trial Disclosure Guidance

Joyce Swart

Alcon Research, LLC, United States

Director, Clinical Trial Disclosure

Have an account?